Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Clinical Characteristics and Risk Factors of Polymyositis and Dermatomyositis Combined with Interstitial Lung Disease in Patients Residing in the Northeast Sichuan Province of China

Author(s): Tao Li, Zi-Yi Tang, Quan-Bo Zhang, Fan-Ni Xiao, Gui-Lin Jian, Yan Xie, Jian-Wei Guo and Yu-Feng Qing*

Volume 19, Issue 4, 2023

Published on: 18 April, 2023

Page: [455 - 462] Pages: 8

DOI: 10.2174/1573397119666230330082452

Price: $65

Abstract

Background: Polymyositis (PM) and dermatomyositis (DM) are non-suppurative and autoimmune inflammatory diseases of striated muscle. Interstitial lung disease (ILD) is a group of heterogeneous diseases that mainly involve the pulmonary interstitium, alveoli, and/or bronchioles, also known as diffuse parenchymal lung disease (DPLD). A significant cause of death in persons with polymyositis (PM) and dermatomyositis (DM) is concurrent interstitial lung disease (ILD). However, research on the clinical characteristics and associated influencing factors of PM/DM combined with ILD (PM/DM-ILD) is currently scarce in China.

Objective: The study aimed to probe the clinical features and risk factors of PM/DM-ILD.

Methods: The data of 130 patients with PM/DM were gathered. General medical status, clinical symptoms, laboratory parameters, high-resolution CT, therapeutic outcomes, and prognoses were retrospectively reviewed in patients with PM/DM with (ILD group) and without (NILD) ILD.

Results: The age of the ILD group (n=65) was more than the NILD group (n=65), and the difference was statistically significant; there were no significant between-group variations in the PM/DM ratio, sex, or duration of the disease. The initial symptoms were arthritis and respiratory symptoms in the ILD group, and myasthenia symptoms in the NILD group. Incidences of Raynaud’s phenomenon, dry cough, expectoration, dyspnea on exertion, arthritis, fever, total globulin (GLOB), erythrocyte sedimentation rate (ESR), and anti-Jo-1 antibody rate were higher for ILD; however, albumin (ALB), creatine kinase aspartate aminotransferase activity ratio (CK/AST) and CK levels were significantly lower in the ILD group. Bivariate logistic regression analysis showed age, dry cough, arthritis, dyspnea on exertion, anti-Jo-1 antibody, and elevated GLOB to be independent risk factors for ILD among patients with PM/DM.

Conclusion: Advanced age, dry cough, arthritis, dyspnea on exertion, anti-Jo-1 antibody positivity, and elevated GLOB level are risk factors for PM/DM-ILD. This information could be utilized to carefully monitor changing lung function in these patients.

« Previous Next »
Graphical Abstract

[1]
Lega JC, Reynaud Q, Belot A, Fabien N, Durieu I, Cottin V. Idiopathic inflammatory myopathies and the lung. Eur Respir Rev 2015; 24(136): 216-38.
[http://dx.doi.org/10.1183/16000617.00002015] [PMID: 26028634]
[2]
Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292(7): 344-7.
[http://dx.doi.org/10.1056/NEJM197502132920706] [PMID: 1090839]
[3]
Group of Pulmonary Vascular and Interstitial Diseases Associated with Rheumatic Diseases, Chinese Association of Rheumatology and Immunology Physicians. Chinese Rheumatic Disease Data Center. 2018 Chinese expert-based consensus statement regarding the diagnosis and treatment of interstitial lung disease associated with connective tissue diseases. Zhonghua Nei Ke Za Zhi 2018; 57(8): 558-65.
[4]
Ha YJ, Lee YJ, Kang EH. Lung involvements in rheumatic diseases: Update on the epidemiology, pathogenesis, clinical features, and treatment. BioMed Res Int 2018; 2018: 1-19.
[http://dx.doi.org/10.1155/2018/6930297] [PMID: 29854780]
[5]
Johnson C, Rosen P, Lloyd T, et al. Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis. Respir Med 2017; 130: 52-4.
[http://dx.doi.org/10.1016/j.rmed.2017.07.010] [PMID: 29206633]
[6]
Song JS, Hwang J, Cha HS, Jeong BH, Suh GY, Chung MP, et al. Significance of myositis autoantibody in patients with idiopathic interstitial lung disease. Yonsei Med J 2015; 56(3): 676-83.
[http://dx.doi.org/10.3349/ymj.2015.56.3.676]
[7]
Yasuda H, Ikeda T, Hamaguchi Y, Furukawa F. Clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia: The relation between the disease activity and the serum interleukin-6 level. J Dermatol 2017; 44(10): 1164-7.
[http://dx.doi.org/10.1111/1346-8138.13887] [PMID: 28543432]
[8]
Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2005; 17(6): 701-6.
[http://dx.doi.org/10.1097/01.bor.0000179949.65895.53] [PMID: 16224246]
[9]
Zhang L, Wu G, Gao D, et al. Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: A systematic review and meta-analysis. PLoS One 2016; 11(5): e0155381.
[http://dx.doi.org/10.1371/journal.pone.0155381] [PMID: 27171228]
[10]
Cen X, Zuo C, Yang M, Yin G, Xie Q. A clinical analysis of risk factors for interstitial lung disease in patients with idiopathic inflammatory myopathy. Clin Dev Immunol 2013; 2013: 1-4.
[http://dx.doi.org/10.1155/2013/648570] [PMID: 24106519]
[11]
Ye S, Chen X, Lu X, et al. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: A retrospective cohort study. Clin Rheumatol 2007; 26(10): 1647-54.
[http://dx.doi.org/10.1007/s10067-007-0562-9] [PMID: 17308858]
[12]
Takada T, Suzuki E, Nakano M, et al. Clinical features of polymyositis/dermatomyositis with steroid-resistant interstitial lung disease. Intern Med 1998; 37(8): 669-73.
[http://dx.doi.org/10.2169/internalmedicine.37.669] [PMID: 9745852]
[13]
Kameda H, Takeuchi T. Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis. Endocr Metab Immune Disord Drug Targets 2006; 6(4): 409-15.
[http://dx.doi.org/10.2174/187153006779025775] [PMID: 17214587]
[14]
Saadoun D, Garrido M, Comarmond C, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol 2015; 67(5): 1353-60.
[http://dx.doi.org/10.1002/art.39037] [PMID: 25604824]
[15]
Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362(9388): 971-82.
[http://dx.doi.org/10.1016/S0140-6736(03)14368-1] [PMID: 14511932]
[16]
Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: Longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59(5): 677-85.
[http://dx.doi.org/10.1002/art.23571] [PMID: 18438901]
[17]
Li T, Guo L, Chen Z, et al. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep 2016; 6(1): 33226.
[http://dx.doi.org/10.1038/srep33226] [PMID: 27615411]
[18]
Miura Y, Saito T, Fujita K, et al. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31(3): 235-8.
[PMID: 25363224]
[19]
Mullerpattan JB, Udwadia ZF, Balakrishnan C, Richeldi L. Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India 2015; 32(1): 50-2.
[http://dx.doi.org/10.4103/0970-2113.148451] [PMID: 25624597]
[20]
Sun Y, He Y, Liu Y, Shi G. Biologics in polymyositis and dermatomyositis-associated interstitial lung disease. Curr Pharm Biotechnol 2014; 15(6): 521-4.
[http://dx.doi.org/10.2174/138920101506140910145940] [PMID: 25213360]
[21]
Fathi M, Barbasso Helmers S, Lundberg IE. KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis. J Intern Med 2012; 271(6): 589-97.
[http://dx.doi.org/10.1111/j.1365-2796.2011.02459.x] [PMID: 21950266]
[22]
Lim CH, Tseng CW, Lin CT, et al. The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study. SAGE Open Med 2018; 6: 2050312118781895.
[http://dx.doi.org/10.1177/2050312118781895] [PMID: 29977547]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy